24/7 Market News Snapshot 04 June, 2025 – 60 Degrees Pharmaceuticals, Inc. Common Stock (NASDAQ:SXTP)

June 4, 2025

DENVER, Colo., 04 June, 2025 (www.247marketnews.com) – (NASDAQ:SXTP) are discussed in this article.
60 Degrees Pharmaceuticals, Inc. is witnessing a notable increase in its stock performance, with shares trading at $3.411, reflecting an impressive gain of approximately 17.22% from the prior closing of $2.910. This upward movement comes amid substantial trading volume of 2.09 million shares, signaling strong investor interest and enhancing the potential for continued growth. Positive market sentiment appears to be a contributing factor to this price action, suggesting momentum that traders should closely monitor for key resistance levels and volume patterns.

In a relevant advancement, the company has recently launched an 8-count bottle format for ARAKODA® (tafenoquine), specifically tailored for travelers visiting malaria-endemic areas for shorter durations. This new packaging aims to improve accessibility and aid healthcare professionals in prescribing ARAKODA to those requiring malaria prophylaxis for trips lasting a week or less.

ARAKODA stands out as the sole weekly prophylactic treatment that safeguards against both the blood and liver stages of malaria, instilling a sense of assurance for travelers. The new 8-count bottles are now available through major retail pharmacies, including online platforms, facilitating easier access to this essential medication.

Since gaining approval in 2018, ARAKODA has become a crucial option in malaria prevention, administered through a straightforward regimen of 2 x 100 mg tablets during an initial loading phase, followed by continued use throughout the journey. With a prolonged terminal half-life of approximately 16 days, ARAKODA enhances patient adherence by reducing the frequency of dosing.

60 Degrees Pharmaceuticals remains committed to tackling infectious diseases through innovation, with ARAKODA exemplifying the company’s dedication to advancing public health and enhancing the quality of life for individuals at risk of malaria. Healthcare providers and patients are urged to consult professionals regarding the suitability of ARAKODA for their specific needs while considering significant safety information and contraindications.

Related news for (SXTP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.